González Santiago, Santiago | Oncología

Resultados: 57
Tipo Título / Nombre Autor(es) Año
Constructing a high-definition patient-digital twin (PDT) in treatment-naïve women with advanced cancer Garma LD, Jiménez D, Vicente Baz D..., González S 2024
Long-term responders (LTR) with niraparib maintenance in platinum-sensitive recurrent high-grade serous ovarian cancer (PSROC) focusing on subsequent therapies and postprogression outcomes (GEICO-88R study) Cuevas Banuelos JF, García García Y, Yubero Esteban A, Gallego Martinez A..., González S 2024
Ipatasertib (IPA) combined with non-taxane chemotherapy (CT) for patients (pts) with previously treated advanced triple-negative breast cancer (aTNBC): The PATHFINDER phase IIa trial López Miranda E, Pérez García JM, Gion M..., González Santiago S 2024
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer Torres-Esquius S, Llop-Guevara A, Gutiérrez-Enríquez S, Romey M..., Santiago González S 2024
Preventing alpelisib-related hyperglycaemia in HR+/HER2?/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial Llombart Cussac A, Pérez García J, Ruiz Borrego M, Tolosa P..., González Santiago S 2024
Use of multi-gene panels in patients at high risk of hereditary digestive cancer: position statement of AEG, SEOM, AEGH and IMPaCT-GENÓMICA consortium Carballal S, Balaguer F, Bujanda L, Capellá G, Santiago SG, Jover R, Moreira L, Pineda M, Ponte CR, Sánchez Heras AB, Blanch RS, Soto JL, Tocino RV, Cubiella J, en representación de AEG, SEOM, AEGH y consorcio IMPaCT-Genómica 2024
Olaparib (O) in advanced triple negative breast cancer (aTNBC) patients (pts) with BRCA1/2 promoter methylation: GEICAM/2015-06 study (COMETA-Breast) Haba J de la, Anton A, Quiroga V..., Santiago González S 2023
A phase 2 randomized pre-operative,window of opportunity trial investigating the effect of elacestrant with/without triptorelin in premenopausal patients with HR+/HER2- breast cancer – SOLTI-2104-PremiÈRe trial Bellet Ezquerra M, Hernando C, Tolosa P..., González Santiago S 2023
Lower pre-treatment B-cell gene expression signatures correspond with improved overall survival with palbociclib + endocrine therapy in HR+/HER2- metastatic breast cancer: a biomarker analysis from the GEICAM/2013-02 PEARL trial Agrawal Y, Fernández Martínez A, Gil Gil M..., González Santiago S 2023
Randomized Phase II trial evaluating three anti-diarrhoeal prophylaxis strategies in patients with HER2+/HR+ early breast cancer treated with extended adjuvant neratinib (DIANER GEICAM/2018-06) Gil Gil M, Martín M, Carrasco E..., González Santiago S 2023